A team of researchers led by Hsueh-Chia Chang at the University of Notre Dame has created a new diagnostic platform that can screen for four serious diseases—colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer's disease—using just a small blood sample, with results available in about an hour, according to a study published in Nature Biomedical Engineering.

The technology was tested in a blind setting using 87 plasma samples from patients who were either healthy or had one of the four conditions. The platform correctly identified the presence or absence of each disease with 90 to 99 percent accuracy, the university reported.

“We believe that if we can screen these diseases earlier, then patients may have a better chance at surviving,” said Chang, the Bayer Corporation Professor of Engineering in the Department of Chemical and Biomolecular Engineering at Notre Dame.

For students and researchers in biomedical engineering, the work represents a potential shift toward faster, cheaper, and more accessible diagnostic tools. The platform is designed to be low-cost and intentionally fast, which could make it suitable for use in routine checkups or in settings where laboratory infrastructure is limited.

How the test works

The detection platform relies on exosomes—tiny vesicles released by cells that carry proteins indicative of disease. To spot these markers, Chang's lab developed what they call immunojanus particles: microscopic spheres with two distinct halves. One half is coated with antibodies that latch onto disease-specific proteins on exosomes; the other half is fluorescent.

To run a test, a 10-microliter blood sample—roughly a fifth of a typical lab draw—is diluted with saline and mixed with the immunojanus particles for 10 to 60 minutes. As the particles disperse, the antibodies bind to target proteins on exosomes. The mixture is then examined under a microscope.

The fluorescent half of each particle is key: when a disease marker is present, the bound particles exhibit a characteristic twinkling motion. Chang and his team wrote a proprietary computer program that analyzes this movement using Brownian motion—the random, erratic jitter of microscopic particles in fluid—to determine whether a disease marker is present.

“We had to overcome the interference issue, and immunojanus particles can because they are both sensitive and selective,” Chang said. “Sensitive because we can detect a single exosome on an immunojanus particle from the blinking frequency, and selective because other small molecules do not produce a signal.”

Accuracy and next steps

The platform's accuracy—between 90 and 99 percent depending on the disease—is significantly higher than current leading exosome detection technologies, according to the researchers. The study was funded by the National Institutes of Health.

While the results are promising, the test has so far only been validated on 87 samples in a controlled laboratory setting. Larger clinical trials would be needed before the platform could be approved for routine medical use. The researchers have filed a patent for the technology but have not announced a timeline for commercial development or clinical deployment.

For university students studying medicine, bioengineering, or public health, the development illustrates how interdisciplinary approaches—combining materials science, fluid dynamics, and computer vision—can address longstanding challenges in early disease detection.